CARM
Carisma Therapeutics, Inc.0.0500
+0.0020+4.17%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
2.09MP/E (TTM)
0.26Basic EPS (TTM)
0.19Dividend Yield
0%Recent Filings
8-K
Delisting and leadership shift
Carisma Therapeutics approved voluntary Nasdaq delisting on December 4, 2025, filing Form 25 around December 10 for effectiveness 10 days later, followed by Form 15 to end SEC reporting. Amid wind-down, VP Finance Natalie McAndrew resigns December 31; Steven Kelly steps in as interim CEO until year-end, succeeded January 1 by wind-down specialist Craig Jalbert at $50,000 yearly. Three directors also exit December 31. Delisting accelerates deregistration.
10-Q
Q3 FY2025 results
Carisma swung to Q3 operating income of $43.8M from a $13.1M loss y/y, fueled by $45.3M collaboration revenue—up from $3.4M—via full recognition of prior Moderna deferred revenue plus a $4.0M amendment payment that ended future obligations. Expenses plunged 91% to $1.4M as R&D halted post-84% workforce cut. Cash drained to $2.8M, with $14.1M YTD operating burn; no debt, but Nasdaq delisting hit October 13. OrthoCellix merger terminated September 16 over unmet $25M financing. Wind down accelerates. Nasdaq noncompliance risks total delisting.
8-K
Leadership exits in wind-down
Carisma terminated CEO Steven Kelly (effective Nov 15, 2025) and CSO Michael Klichinsky (effective Oct 15, 2025) without cause amid asset sale pursuit and wind-down. Kelly gets $624,000 severance plus $299,948 pro-rata bonus; Klichinsky $494,000 salary continuation and $155,915 bonus. Three directors resigned Oct 15. Consultant to lead wind-down.
8-K
8-K
Merger axed, Moderna cash grabbed
Carisma Therapeutics terminated its merger agreement with OrthoCellix on September 16, 2025, after failing to secure $25.0 million in concurrent financing, including Ocugen's $5.0 million commitment. It also amended its Moderna collaboration, securing a $4.0 million one-time payment that eliminates all future royalties and milestones. Cash preserves runway. Now pursuing asset sales or wind-down amid Nasdaq delisting risk.
CAI
Caris Life Sciences, Inc.
27.60+0.90
CBIO
Crescent Biopharma, Inc.
12.92-0.29
CLLS
Cellectis S.A.
4.06-0.73
CMMB
Chemomab Therapeutics Ltd.
2.06+0.00
COEP
Coeptis Therapeutics Holdings,
14.43-0.66
CRBU
Caribou Biosciences, Inc.
1.69-0.02
FATE
Fate Therapeutics, Inc.
1.09-0.03
GTBP
GT Biopharma, Inc.
0.72+0.09
LSTA
Lisata Therapeutics, Inc.
2.05+0.01
MBIO
Mustang Bio, Inc.
1.07-0.06